<scp>CXCL</scp>‐10 and Interleukin‐6 are reliable serum markers for vitiligo activity: A multicenter cross‐sectional study

Abdallah, Marwa; El‐Mofty, Medhat; Anbar, Tag S.; Rasheed, Hoda; Esmat, Samia; Al-Tawdy, Amira; Fawzy, Marwa M.; Abdel-Halim, Dalia; Hegazy, Rehab A.; Gawdat, Heba I.; Bassiouny, Dalia Ahmed; Ibrahim, Mona Abdel-Halim; Sany, Iman; Elbassiouny, M.; Khalil, Mohamed; Abdelaziz, Ayman Ahmed; Maadawi, Zeinab M. El; Mostafa, Wedad Z.

doi:10.1111/pcmr.12667

Cited by 54 publications

(48 citation statements)

References 33 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of initially identified 165 citations, 11 studies including 626 vitiligo patients and 475 controls were finally selected . The study selection process using PRISMA flow chart is shown in Figure , and the characteristics of the included studies are shown in Table .…”

Section: Resultsmentioning

confidence: 99%

Interleukin‐17 level in patients with vitiligo: A systematic review and meta‐analysis

Acharya

Mathur

2020

Aust J Dermatology

View full text Add to dashboard Cite

Background/Objectives: The role of the pro-inflammatory cytokine, interleukin (IL)-17 is being continuously explored in various autoimmune disorders. Studies have assessed the levels of IL-17 in vitiligo patients. This study aims to evaluate the IL-17 levels in vitiligo patients in comparison with the healthy controls by performing a meta-analysis.Methods: A systematic review of the existing literature was performed in PubMed, Scopus and Cochrane databases by two authors independently. The data required to calculate the pooled effect size in the form of standardised mean difference (SMD) with the corresponding 95% confidence interval (CI) were extracted from the eligible studies. Separate analyses for active and stable vitiligo were also performed.Results: A total of 11 case-control studies with 626 vitiligo patients and 475 healthy controls were included. Random-effects meta-analysis found significantly higher serum IL-17 levels in vitiligo patients compared with the healthy controls (SMD = 1.67, 95% CI 1.11 to 2.22, P < 0.001). The IL-17 levels were higher in both active (SMD = 1.31, 95% CI 0.76 to 1.86) and stable (SMD = 1.47, 95% CI 0.59 to 2.35) vitiligo patients compared with the healthy controls. The skin IL-17 levels were also significantly higher in vitiligo patients (SMD = 1.28, 95% CI 0.82 to 1.74). Heterogeneity in the baseline characteristics of the included studies was the major limitation of this study.Conclusions: These results suggest that vitiligo patients have significantly elevated IL-17 levels. Further examination of this association could have implications for the treatment of vitiligo.

show abstract

Section: Resultsmentioning

confidence: 99%

Interleukin‐17 level in patients with vitiligo: A systematic review and meta‐analysis

Acharya

Mathur

2020

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…Recently, the elevated level of serum C‐X‐C motif chemokine (CXCL)10 has been reported as a poor prognostic marker for melanoma patients 25,26 . Serum level of CXCL10 is also reported to be elevated, and tissue CXCL10‐positive cell expression was stronger in extensive, active vitiligo patients without melanoma 27 . Although the serum level of CXCL10 was not investigated in the present study, unfortunately, CXCL10 may have a certain association with disease progression and vitiligo expansion in such melanoma patients with vitiligo who did not show a response.…”

Section: Discussionmentioning

confidence: 99%

Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study

Matsuya

Nakamura

Matsushita

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti-programmed death 1 (PD-1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti-PD-1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression-free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti-PD-1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression-free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti-PD-1 antibody in melanoma patients.

show abstract

“…The mRNA and protein expression levels of IFN-g or type I IFN were shown to be increased in the blood samples of patients with active vitiligo compared with those of patients with stable disease or healthy controls (Briggs et al, 2011;Dwivedi et al, 2013). The IFN-specific signature or IFN-producing cells were also elevated in the blood or skin lesions (Abdallah et al, 2018;Badri et al, 1993;Bertolotti et al, 2014;Rashighi et al, 2014;Yang et al, 2015). Overall, there appears to be a strong association between IFN and melanocytes destruction as well as vitiligo development.…”

Section: Discussionmentioning

confidence: 94%

Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation

Liu

Guo

et al. 2019

Cell Reports

View full text Add to dashboard Cite

Graphical Abstract Highlights d Suspensive system enhances efficiency of hiPSC differentiation into melanocytes d hiMelanocyte stem cells in bulge region provide long-term function maintenance d Mature hiMelanocytes integrate into the mouse hair bulb and produce melanin d Patient iMelanocytes reveal multiple vitiligo-associated signaling pathways SUMMARYInduced pluripotent stem cells (iPSCs) are a promising melanocyte source as they propagate indefinitely and can be established from patients. However, the in vivo functions of human iPSC-derived melanocytes (hiMels) remain unknown. Here, we generated hiMels from vitiligo patients using a three-dimensional system with enhanced differentiation efficiency, which showed characteristics of human epidermal melanocytes with high sequence similarity and involved in multiple vitiligo-associated signaling pathways. A modified hair follicle reconstitution assay in vivo showed that MITF + PAX3 + TYRP1 + hiMels were localized in the mouse hair bulb and epidermis and produced melanin up to 7 weeks after transplantation, whereas MITF + PAX3 + TYRP1 À hiMelanocyte stem cells integrated into the bulge-subbulge regions.Overall, these data demonstrate the long-term functions of hiMels in vivo to reconstitute pigmented hair follicles and to integrate into normal regions for both mature melanocytes and melanocyte stem cells, providing an alternative source of personalized cellular therapy for depigmentation.

show abstract

CXCL‐10 and Interleukin‐6 are reliable serum markers for vitiligo activity: A multicenter cross‐sectional study

Cited by 54 publications

References 33 publications

Interleukin‐17 level in patients with vitiligo: A systematic review and meta‐analysis

Interleukin‐17 level in patients with vitiligo: A systematic review and meta‐analysis

Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study

Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation

Contact Info

Product

Resources

About